Cutera, Inc. (NASDAQ:CUTR) Director David B. Apfelberg sold 1,000 shares of the company’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $42.55, for a total value of $42,550.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

David B. Apfelberg also recently made the following trade(s):

  • On Monday, September 18th, David B. Apfelberg sold 1,000 shares of Cutera stock. The stock was sold at an average price of $38.45, for a total value of $38,450.00.

Cutera, Inc. (NASDAQ CUTR) traded down $1.50 during trading hours on Monday, reaching $41.00. 387,351 shares of the company’s stock traded hands, compared to its average volume of 142,565. Cutera, Inc. has a one year low of $14.60 and a one year high of $47.15. The stock has a market capitalization of $574.21, a price-to-earnings ratio of 54.49, a price-to-earnings-growth ratio of 1.84 and a beta of 0.49.

Cutera (NASDAQ:CUTR) last posted its quarterly earnings results on Tuesday, November 7th. The medical device company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.08 by $0.34. Cutera had a net margin of 7.99% and a return on equity of 18.73%. The company had revenue of $38.17 million for the quarter, compared to analyst estimates of $34.82 million. During the same period in the prior year, the company earned $0.12 earnings per share. The firm’s revenue was up 26.1% on a year-over-year basis. equities research analysts anticipate that Cutera, Inc. will post 0.55 EPS for the current fiscal year.

Cutera announced that its board has initiated a stock repurchase program on Monday, August 7th that permits the company to buyback $25.00 million in outstanding shares. This buyback authorization permits the medical device company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

ILLEGAL ACTIVITY WARNING: “Cutera, Inc. (CUTR) Director Sells $42,550.00 in Stock” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/cutera-inc-cutr-director-sells-42550-00-in-stock/1716545.html.

Several hedge funds have recently bought and sold shares of the company. Parallel Advisors LLC purchased a new stake in shares of Cutera during the 3rd quarter worth about $117,000. Argent Capital Management LLC purchased a new stake in shares of Cutera during the 3rd quarter worth about $1,320,000. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of Cutera by 76.0% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 85,700 shares of the medical device company’s stock worth $3,542,000 after acquiring an additional 37,000 shares in the last quarter. PEAK6 Investments L.P. boosted its stake in shares of Cutera by 533.0% during the 3rd quarter. PEAK6 Investments L.P. now owns 64,895 shares of the medical device company’s stock worth $2,683,000 after acquiring an additional 54,643 shares in the last quarter. Finally, Mackenzie Financial Corp purchased a new stake in shares of Cutera during the 3rd quarter worth about $277,000. 87.81% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts recently issued reports on CUTR shares. Roth Capital upped their target price on Cutera from $41.00 to $47.00 and gave the company a “buy” rating in a research report on Tuesday, September 12th. Gabelli reissued a “buy” rating on shares of Cutera in a research report on Wednesday, August 9th. BidaskClub raised Cutera from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th. TheStreet raised Cutera from a “c” rating to a “b” rating in a research report on Friday, August 18th. Finally, Maxim Group downgraded Cutera from a “buy” rating to a “hold” rating in a research report on Thursday, September 14th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $37.33.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Insider Buying and Selling by Quarter for Cutera (NASDAQ:CUTR)

Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.